Skip to content
type1.science

SOOIL Dana-i

SOOIL Development Co. (distributed in UK/EU by Advanced Therapeutics)

What it is

A compact, lightweight Bluetooth-enabled tubed pump that is the delivery hardware behind the Dana CamAPS FX hybrid closed loop and a supported pump for AndroidAPS open-source AID. Available in the UK; US availability was not confirmed in the sources read.

Editorial review: .

Most recent recorded citation date: 2026-06-30. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Available nowRegulator-approvedpumptubeddurablephone-control

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
Benefit or performance
Reliability: Hardware occlusion/low-reservoir alarms and a published RCT plus 24-week continuation phase (48 weeks total); the main trial reported no DKA or severe hypoglycemia in either group.Read the supporting discussion; this assessment has no individually linked citation.
Important harms and treatment burden
Read the safety discussion and original sources. A missing summary does not establish safety.
Approval and country access
Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Read the full discussion and original sources for follow-up duration and study limitations.

This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

Editorial score: calculation and evidence

A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.

Default calculation: 88 × 20 + 78 × 20 + 55 × 20 + 85 × 15 + 80 × 10 + 55 × 15 = 7320; divide by total weight 100. Unrounded weighted result: 73.2.

Interoperability88

Drives the CamAPS FX loop (Dexcom G6) and is a supported pump for AndroidAPS open-source AID; Diabeloop describes DBLG2 compatibility with Dana-i as coming soon in Europe.

Reliability78

Hardware occlusion/low-reservoir alarms and a published RCT plus 24-week continuation phase (48 weeks total); the main trial reported no DKA or severe hypoglycemia in either group.

Form factor55

Tubed pump (not tubeless/patch), but among the smallest and lightest durable pumps at ~86 g with a waterproof design.

Phone control85

Full discrete bolus and settings control from the AnyDANA app on Android and iOS, plus bolus initiated from the CamAPS FX / AndroidAPS phone app.

Capacity80

300-unit (3.0 mL) reservoir covers most users for ~3 days; replaceable AAA battery lasts about 2–3 weeks.

Access & cost55

Available in the UK through its UK distributor; EU/Asia availability, NHS/insurer funding and out-of-pocket costs were not confirmed from opened sources; no US marketing was found in the sources read.

The full picture

The Dana-i (SOOIL Development, distributed in the UK by Advanced Therapeutics) is a tubed durable insulin pump — not a patch/tubeless device. Insulin runs from the pump body through a thin tube to a separate infusion set on the skin. What makes it notable is not its form factor but its openness: it is the delivery hardware behind the Dana CamAPS FX hybrid closed loop and a supported pump for AndroidAPS, the open-source automated insulin delivery (AID) app.56

Size, reservoir and wear. It is one of the smallest and lightest durable pumps in the world, about 86 g including the battery, and holds a 300-unit (3.0 mL) reservoir.78 That reservoir lasts most people the standard ~3 days between set changes. It has a waterproof design and runs on a single replaceable AAA battery that lasts roughly 2–3 weeks — swapped in seconds, with no overnight charging.78 It uses proprietary SOOIL infusion sets, reservoirs and cannulas.7

Occlusion detection and reliability. The pump has hardware alarms for occlusion, low reservoir, low battery and missed bolus.7 Its strongest reliability evidence is clinical: the randomized CREATE trial (2022) paired a preproduction Dana-i with Dexcom G6 and AndroidAPS and raised time-in-range by 14 percentage points versus a sensor-augmented pump, with no diabetic ketoacidosis or severe hypoglycemia in either trial group.9 A 24-week continuation phase (48 weeks total) extended follow-up.10

CGMs, algorithms and DIY. Through CamAPS FX, the Dana-i closes the loop with Dexcom G6.11 Through AndroidAPS, it runs the open-source OpenAPS algorithm — the same DIY pathway validated in the CREATE trial and in earlier work on the closely related Dana RS pump.512

Phone bolusing. Bolusing is genuinely phone-first: the AnyDANA app (Android and iOS) gives full discrete remote control, and in a loop the bolus is delivered straight from the CamAPS FX or AndroidAPS phone app.76

Access by region. The Dana-i is available in the UK through its UK distributor; EU and Asia availability, NHS/insurer funding routes and private costs were not confirmed from opened sources in this pass. No US marketing was found in the sources read.6

What's coming. Diabeloop says DBLG2 is already available with Kaleido and is coming soon with Dana-i, but that is a European product update with no date.1 It is not evidence of a US Dana-i launch. FDA clearance K251152 covers the DBLG2 algorithm as an interoperable automated glycemic controller; it does not clear Dana-i hardware.3 Diabeloop's announced US integration is instead with Sequel's twiist, targeted for readiness by the end of 2026 and launch in 2027.2 No verified US Dana-i commitment or timeline remains.

CamAPS software safety updates. CamDiab’s notices retire affected Android app versions below 1.4(192) from 31 August 2026 for cybersecurity reasons. Pump, country, phone and sensor determine the applicable app build. Its September notices also advise checking CGM compatibility before an operating-system update. Use the manufacturer’s current notification and compatibility instructions for the exact configuration.13

What's next for this

  • →European DBLG2 compatibility; Diabeloop says Dana-i support is coming soon · no date announced

Sources

  1. [1]
    Diabeloop says DBLG2 availability with Dana-i is coming soon · Manufacturer · 2026-06-30 — European product update: DBLG2 is available with Kaleido and described as coming soon with Dana-i. It does not announce US Dana-i availability.

    Diabeloop. Diabeloop Unveils New DBLG2 Demo App (30 June 2026; product-status section says DBLG2 is available with Kaleido and soon with Dana-i).

  2. [2]
    Diabeloop and Sequel partner for a US DBLG2/twiist system · Manufacturer · 2026-01-14 — The announced US hardware partner is Sequel's twiist, with product readiness targeted by end-2026 and launch in 2027. Dana-i is not the pump named for the US route.

    Diabeloop and Sequel Med Tech. Partnership to integrate FDA-cleared DBLG2 into the twiist AID system (14 January 2026; target readiness end-2026, US launch 2027).

  3. [3]
    FDA 510(k) K251152 — DBLG2 interoperable automated glycemic controller · Regulatory decision · 2025-12-19 — Clears the DBLG2 algorithm as an iAGC. It does not clear Dana-i pump hardware or a DBLG2/Dana-i system for the United States.

    U.S. FDA. 510(k) K251152 — DBLG2 interoperable automated glycemic controller (decision 19 December 2025).

  4. [4]
  5. [5]

    AndroidAPS Documentation. DanaRS and Dana-i Pump. androidaps.readthedocs.io (accessed 2026). https://androidaps.readthedocs.io/en/latest/CompatiblePumps/DanaRS-Insulin-Pump.html

  6. [6]

    Advanced Therapeutics (UK) Ltd. Dana CamAPS FX. advancedtherapeutics.org.uk (accessed 2026). https://www.advancedtherapeutics.org.uk/dana-camaps-fx/

  7. [7]

    SOOIL Development. Diabecare Dana-i Insulin Pump — product specifications. SOOIL (accessed 2026). https://www.sooil.com/eng/product/

  8. [8]

    Advanced Therapeutics (UK) Ltd. The Dana i System. advancedtherapeutics.org.uk (accessed 2026). https://advancedtherapeutics.org.uk/shop/dana-diabecare-insulin-pump/dana-i-insulin-pump/

  9. [9]

    Burnside MJ, Lewis DM, Crocket HR, et al. Open-Source Automated Insulin Delivery in Type 1 Diabetes. New England Journal of Medicine 387:869-881 (2022). PMID 36069869. https://doi.org/10.1056/NEJMoa2203913

  10. [10]

    Burnside MJ, Lewis DM, Crocket HR, et al. Extended Use of an Open-Source Automated Insulin Delivery System: The 24-Week Continuation Phase Following the CREATE Randomized Controlled Trial. Diabetes Technology & Therapeutics 25:250-259 (2023). PMID 36763345. https://doi.org/10.1089/dia.2022.0484

  11. [11]

    Dexcom. Dana CamAPS FX — Integrations and Partnerships. dexcom.com (accessed 2026). https://www.dexcom.com/en-gb/integrations-and-connectivity/insulin-pumps/dana-camaps-fx

  12. [12]

    Gawrecki A, Zozulinska-Ziolkiewicz D, Michalak MA, et al. Safety and glycemic outcomes of do-it-yourself AndroidAPS hybrid closed-loop system in adults with type 1 diabetes. PLOS ONE 16:e0248965 (2021). PMID 33819289. https://doi.org/10.1371/journal.pone.0248965

  13. [13]